|
Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB. |
|
|
Honoraria - Bayer; Five Prime Therapeutics; Genentech; Lilly/ImClone; Novartis; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda |
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly |
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; PFIZER; Roche; Sandoz; Teva |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Teva |
Travel, Accommodations, Expenses - ADPharma; Astellas Pharma; Janssen; PFIZER; Teva |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; Astellas Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Mylan; Novartis; Pfizer; Pharma Marathi; Roche |
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
Research Funding - Lilly; MSD; Roche |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche; Sanofi |
|
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
No Relationships to Disclose |